Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Next Previous
Search
Trial Profile

Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caficrestat (Primary)
  • Indications Diabetic cardiomyopathy; Diabetic neuropathies
  • Focus Registrational; Therapeutic Use
  • Acronyms ARISE-HF
  • Sponsors Applied Therapeutics

Most Recent Events

  • 19 Jul 2024 Last checked against ClinicalTrials.gov record.
  • 09 May 2024 According to an Applied Therapeutics media release, full results from this study were presented at the 2024 American College of Cardiology Annual Scientific Session and published in the Journal of the American College of Cardiology (JACC).
  • 04 Apr 2024 According to an Applied Therapeutics media release, full results from the study will be presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Scientific Session to take place April 6-8, 2024 in Atlanta, Georgia.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top